Ligand Set For Partnership Opportunities After Completing On Pfenex
Sets Out Strategy And Revenue Drivers After Finalizing $500m Deal
Fresh from completing its acquisition of Pfenex, Ligand Pharmaceuticals has laid out the benefits that it expects to gain from the deal.
You may also be interested in...
After launching in the US last year, the teriparatide product developed by Pfenex and Alvogen has been introduced in Europa, via commercialization partner Theramex, beginning with Germany.
Mergers and acquisitions have long been a tool for value creation in the generics and biosimilars space. Even with the entire life sciences sector overwhelmed by the novel coronavirus pandemic, deals big and small continued in 2020.
Ligand Pharmaceuticals has struck a deal to acquire Pfenex in a transaction valued at up to $516m.